<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609944</url>
  </required_header>
  <id_info>
    <org_study_id>1922</org_study_id>
    <secondary_id>U01DK116743</secondary_id>
    <nct_id>NCT03609944</nct_id>
  </id_info>
  <brief_title>SpHincterotomy for Acute Recurrent Pancreatitis</brief_title>
  <acronym>SHARP</acronym>
  <official_title>SpHincterotomy for Acute Recurrent Pancreatitis (SHARP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregory A. Cote</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a procedure called Endoscopic Retrograde
      CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the
      number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with
      sphincterotomy is a procedure where doctors used a combination of x-rays and an endoscope (a
      long flexible lighted tube) to find the opening of the duct where fluid drains out of the
      pancreas. People who have been diagnosed with pancreas divisum, have had at least two
      episodes of pancreatitis, and are candidates for the ERCP with sphincterotomy procedure may
      be eligible to participate. Participants will be will be randomly assigned to either have the
      ERCP with sphincterotomy procedure, or to have a &quot;sham&quot; procedure. Participants will have
      follow up visits 30 days after the procedure, 6 months after the procedure, and continuing
      every 6 months until a maximum follow-up period of 48 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a sham-controlled, single blinded with a blinded outcome assessment, multi-center,
      randomized clinical trial of endoscopic retrograde cholangiopancreatography (ERCP) with minor
      papilla endoscopic sphincterotomy (miES) for the treatment of recurrent acute pancreatitis
      (RAP) with pancreas divisum. ERCP with miES is often offered in clinical practice to patients
      with RAP, pancreas divisum, and no other clear risk factors for their acute pancreatitis
      episodes. The hypothesis is that obstruction at the level of the minor papilla is one cause
      of RAP in pancreas divisum; miES will relieve the obstruction, thereby reducing the risk of a
      recurrent attack(s) of acute pancreatitis. The trial requires a total sample size of
      approximately 234 subjects, and a planned enrollment period of approximately 3.5 years with
      total planned study duration of 5 years (minimum follow-up of 6 months, maximum follow-up of
      48 months).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized 1:1 to either EUS+sham or EUS+ERCP with miES.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>In addition to the participant and the investigator assessing outcomes, study coordinators involved in collecting outcomes data will be masked to the treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduce the risk of subsequent acute pancreatitis episodes by 33%</measure>
    <time_frame>This is a time-to-event outcome that is assessed starting 30 days after treatment through a maximum follow-up of 48 months.</time_frame>
    <description>To test this aim, compare the incidence of acute pancreatitis &gt; 30 days after treatment allocation as the primary outcome measure, using the next attack of acute pancreatitis as a time-to-event outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the incidence rate ratio of acute pancreatitis between treatment groups</measure>
    <time_frame>Incidence rate will be assessed starting 30 days after treatment through a maximum follow-up of 48 months.</time_frame>
    <description>All randomized subjects will be followed longitudinally until study completion (minimum follow-up of six months, maximum follow-up of 48 months), even if acute pancreatitis occurs during follow-up. A secondary benefit of miES may be a reduction in acute pancreatitis frequency, defined as the incidence rate (episodes/time pre- and post-randomization). Since baseline incidence rate is a probable predictor of post-randomization incidence rate, the investigators will compare the incidence rate ratios between the two arms, keeping person-time equal between the pre/post periods.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Pancreatitis</condition>
  <condition>Pancreas Divisum</condition>
  <condition>Pancreatitis, Acute</condition>
  <condition>Pancreatitis Idiopathic</condition>
  <condition>Pancreas Inflamed</condition>
  <arm_group>
    <arm_group_label>EUS + Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects randomized to EUS + sham will undergo a diagnostic endoscopic ultrasound (EUS) under sedation. The physician investigator will not make any attempts to achieve minor papilla cannulation, but photo document the minor papilla using a duodenoscope. Diluted dye will be injected into the duodenum. A small caliber prophylactic pancreatic duct stent will be deposited into the duodenal lumen. These maneuvers are performed to minimize the risk of unmasking.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS + ERCP with miES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to EUS + ERCP with miES will undergo the procedure at the same time as endoscopic ultrasound (EUS), under sedation. Indomethacin (100 mg) will be administered rectally at the onset of the ERCP procedure in patients with no known allergy to indomethacin. The techniques used to perform the endoscopic retrograde cholangiopancreatography (ERCP)with miES (minor papilla endoscopic sphincterotomy) will be left to the discretion of the study endoscopist. The extent of sphincterotomy will be per the discretion of the treating endoscopist. Unless methylene blue (or similar chromoendoscopy agent such as indigo carmine) has already been used to facilitate minor papilla cannulation, diluted dye will be injected into the duodenum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERCP with miES</intervention_name>
    <description>Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy</description>
    <arm_group_label>EUS + ERCP with miES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS</intervention_name>
    <description>Endoscopic ultrasound</description>
    <arm_group_label>EUS + ERCP with miES</arm_group_label>
    <arm_group_label>EUS + Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must consent to be in the study and must have signed and dated an approved
             consent form.

          2. &gt;18 years

          3. Two or more episodes of acute pancreatitis, with each episode meeting two of the
             following three criteria:

               -  abdominal pain consistent with acute pancreatitis (acute onset of a persistent,
                  severe, epigastric pain often radiating to the back)

               -  serum lipase activity (or amylase activity) at least three times greater than the
                  upper limit of normal

               -  characteristic findings of acute pancreatitis on CECT, MRI or transabdominal
                  ultrasonography

          4. At least one episode of acute pancreatitis within 24 months of enrollment

          5. Pancreas divisum confirmed by prior MRCP that is reviewed by an abdominal radiologist
             at the recruiting site.

          6. By physician assessment, there is no certain explanation for recurrent acute
             pancreatitis.

          7. Subjects must be able to fully understand and participate in all aspects of the study,
             including completion of questionnaires and telephone interviews, in the opinion of the
             clinical investigator

        Exclusion Criteria:

          1. Prior minor papilla therapy (endoscopic or surgical)

          2. Calcific chronic pancreatitis, defined as parenchymal or ductal calcifications
             identified on computed tomography or magnetic resonance imaging scan that is reviewed
             by an expert radiologist at the recruiting site.

          3. Main pancreatic duct stricture*

          4. Presence of a structural etiology for acute pancreatitis, such as anomalous
             pancreatobiliary union, periampullary mass, or pancreatic mass lesion on imaging*

          5. Presence of a local complication from acute pancreatitis which requires pancreatogram

          6. Regular use of opioid medication for abdominal pain for the past three months

          7. Medication as the etiology for acute pancreatitis by physician assessment

          8. TWEAK score â‰¥ 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory A Cote, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregory Cote, MD, MS</last_name>
    <phone>843-792-6999</phone>
    <email>cotea@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Hyatt</last_name>
      <email>stacyhyatt@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>C. Mel Wilcox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Serna</last_name>
      <phone>323-409-6939</phone>
      <email>SernaJ@USC.edu</email>
    </contact>
    <investigator>
      <last_name>James Buxbaum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janille Miranda</last_name>
      <phone>415-476-4882</phone>
      <email>Janille.Miranda@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa Arain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Rose</last_name>
      <phone>203-984-4007</phone>
      <email>christina.rose@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Priya A. Jamidar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ambreen Merchant</last_name>
      <phone>404-727-6278</phone>
      <email>amerc26@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Field F. Willingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Wood</last_name>
      <phone>312-926-4390</phone>
      <email>jordan.wood1@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Rajesh Keswani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzette Schmidt</last_name>
      <phone>317-948-8104</phone>
      <email>suschmid@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Fogel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghislaine Feussom</last_name>
      <phone>612-626-3636</phone>
      <email>feuss001@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Freeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital System</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Harkness</last_name>
      <phone>816-932-0352</phone>
      <email>jharkness@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Srinivas Jonnalagadda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Doughty</last_name>
      <phone>603-653-6048</phone>
      <email>Penny.J.Doughty@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Gardner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Conley</last_name>
      <phone>614-366-4495</phone>
      <email>brianna.conley@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Darwin Conwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Tomko</last_name>
      <phone>412-647-1120</phone>
      <email>tomkot@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Dhiraj Yadav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Nitchie</last_name>
      <phone>843-876-0487</phone>
      <email>Nitchie@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Cote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esmeralda Martinez</last_name>
      <phone>214-947-4066</phone>
      <email>EsmeraldaMartinez@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Paul R. Tarnasky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Foster</last_name>
      <email>SLF9H@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Hospital &amp; Seattle Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Magbitang</last_name>
      <phone>202-341-1406</phone>
      <email>KatrinaAnn.Magbitang@VirginiaMason.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane McAlpine</last_name>
      <phone>204-787-1643</phone>
      <email>DMcAlpine@hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Dana Moffatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://www.sharpdivisumtrial.com/</url>
    <description>study trial website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Gregory A. Cote</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>Endoscopic retrograde cholangiopancreatography</keyword>
  <keyword>pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

